cisplatin + fluorouracil + S-1

This is a combination chemotherapy regimen consisting of cisplatin, fluorouracil (5-FU), and S-1. - **Cisplatin** is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA synthesis and function, leading to apoptosis in rapidly dividing cells. - **Fluorouracil (5-FU)** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and repair by mimicking uracil and incorporating into RNA and DNA. - **S-1** is an oral fluoropyrimidine derivative composed of tegafur (a prodrug of 5-FU), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU levels), and oteracil potassium (to reduce gastrointestinal toxicity). S-1 increases the efficacy of 5-FU while reducing its side effects[1][3][6]. This combination is primarily used as first-line or perioperative chemotherapy for advanced gastric cancer, esophageal cancer, or nasopharyngeal carcinoma in East Asian clinical practice[1][3][4][5]. The regimen leverages the synergistic cytotoxic effects on tumor cells from both platinum-induced DNA damage and pyrimidine analog-mediated inhibition of nucleotide synthesis.

Other names

顺铂 + 氟尿嘧啶 + 替吉奥